Danika Peterson, MD
Family Medicine · Kearney, NENPI 1760902159
Payments from drug & device makers
Across 142 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$569
- Novo Nordisk$452
- AbbVie$268
- Amgen$220
- Lilly USA, LLC$142
- Novartis$123
- plus $982 from 25 others
What the payments were for
- Food & beverage$2,757100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $569 |
| Novo Nordisk | 22 | $452 |
| AbbVie | 23 | $268 |
| Amgen | 15 | $220 |
| Lilly USA, LLC | 9 | $142 |
| Novartis | 8 | $123 |
| Sanofi-aventis U.S. LLC | 6 | $98 |
| Pfizer | 6 | $93 |
| Astellas Pharma US Inc | 4 | $89 |
| Kerecis Limited | 1 | $85 |
| Merck | 5 | $78 |
| Medtronic | 1 | $67 |
| Boehringer Ingelheim | 5 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| Philips North America LLC | 2 | $40 |
| Johnson & Johnson | 2 | $34 |
| Smith+Nephew | 1 | $31 |
| Sanofi | 1 | $24 |
| Bausch Health US, LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Seagen Inc. | 1 | $18 |
| Roche Diagnostics Corporation | 1 | $17 |
| Organon | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 2 | $11 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$2,757 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $72,325 |
| EliquisApixaban | 76 | $45,763 |
| MounjaroTirzepatide | 43 | $44,743 |
| JardianceEmpagliflozin | 61 | $41,471 |
| XareltoRivaroxaban | 63 | $30,572 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $29,586 |
| MyrbetriqMirabegron | 35 | $16,748 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,506 |
| JanuviaSitagliptin Phosphate | 23 | $14,084 |
| TrintellixVortioxetine Hydrobromide | 26 | $12,288 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $10,363 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $8,190 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,467 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $7,041 |
| RytaryCarbidopa/Levodopa | 20 | $4,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $452 | $72,32570 claims |
| PfizerEliquis, Abrysvo | $93 | $50,20290 claims |
| Lilly USA, LLCMounjaro | $142 | $44,74343 claims |
| Boehringer IngelheimJardiance | $67 | $41,47161 claims |
| Johnson & JohnsonXarelto | $34 | $30,57263 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $16,74835 claims |
| AstraZenecaBreztri Aerosphere | $569 | $16,50626 claims |
| MerckJanuvia | $78 | $14,08423 claims |
| GSKAnoro Ellipta | $15 | $7,46716 claims |
| Sanofi-aventis U.S. LLCLantus | $98 | $1,27817 claims |
| AbbVieSynthroid | $268 | $1,03112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Kearney
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.